OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The agency’s human medicines committee recommended drugs to treat breast cancer, lupus nephritis, type 2 diabetes and more.
The European Medicines Agency (EMA) announced on July 22, 2022 that its Committee for Medicinal Products for Human Use (CHMP) recommended approval for 11 medicines at its July 2022 meeting. The medicines treat a variety of conditions including cancer and type 2 diabetes.
The approved medicines included the following:
The CHMP also granted conditional marketing authorization for Tecvayli (teclistamab) for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies. Tecvayli was processed through EMA’s PRIority MEdicines scheme, which provides early scientific and regulatory support for drugs that treat unmet needs.